Add BrightSurf on Google Email

Study points to new approach to clearing toxic waste from brain

Researchers at Washington University School of Medicine have discovered a new pathway that could help prevent Alzheimer's dementia. Increasing the clearance of waste products in the brain by ramping up a genetic quirk known as readthrough may be effective for other neurodegenerative diseases, such as Parkinson's disease.

SourceWashU Medicine·JournalBrain·TypeExperimental study·DateAug 24, 2022

Sugar metabolism is surprisingly conventional in cancer

Researchers at Washington University in St. Louis found that cancer cells metabolize glucose in their mitochondria, following conventional biochemical patterns. The study suggests that limiting glucose uptake may not be an effective strategy to target cancer cells, and glucose metabolism may need to be reevaluated as a therapeutic target.

SourceWashington University in St. Louis·JournalMolecular Cell·TypeExperimental study·DateAug 15, 2022

Study uncovers what happens inside artery plaque to trigger strokes

A study at Tulane University found that recently formed stroke plaques contain messenger RNA that causes inflammation and degrades a protective cap, leading to rupture. This discovery could lead to new tools to stop strokes from happening and develop new drugs or diagnostics to prevent heart attacks and strokes.

SourceTulane University·JournalScientific Reports·TypeRandomized controlled/clinical trial·DateAug 11, 2022

Prompt recognition and treatment found effective for lung disease in patients who received new drug for advanced cancer

A comprehensive analysis of interstitial lung disease diagnosis and treatment in patients who received an antibody drug conjugate known as T-DXd found that close monitoring and proactive management can reduce the risk of ILD. The study results suggest that patient awareness and ongoing education can aid in early detection.

Oncotarget | Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma

Researchers found that Merkel cell carcinoma (MCC) Glypican-3 (GPC3) is expressed in nearly 70% of MCC tumors and up to 90% of MCPyV-negative cases. GPC3 expression is associated with worse prognosis, including increased risk of death from MCC. This makes GPC3 a promising target for chimeric antigen receptor T cell therapy.

SourceImpact Journals LLC·JournalOncotarget·TypeExperimental study·DateAug 11, 2022

Improving outcomes for injured soldiers

University of Cincinnati researchers are studying whether targeting an inflammation pathway can improve patient results for soldiers with burn injuries combined with traumatic brain injuries. The research focuses on a specific protein that causes inflammation, which can lead to complications such as anemia and death.

Rice models moving ‘washers’ that help DNA replicate

Researchers have modelled a key mechanism by which DNA replicates, revealing details about how helicases wrangle DNA during replication. The simulations showed each step of translocation can travel more than 12 nucleotides along the backbone, pinpointing interactions involved in long-distance movement.

SourceRice University·JournalProceedings of the National Academy of Sciences·TypeComputational simulation/modeling·DateAug 9, 2022

Aldosterone linked to increased risk of chronic kidney disease progression and end-stage kidney disease

Higher aldosterone concentrations are associated with lower eGFR, lower potassium levels in blood, and higher potassium and protein concentrations in urine. The risk of CKD worsening was independent of diabetes status. Finerenone may help prevent CKD progression by targeting aldosterone's action.

SourceEuropean Society of Cardiology·JournalEuropean Heart Journal·TypeObservational study·DateAug 8, 2022

“Good evidence” that ADHD drugs might also treat Alzheimer’s disease

A pooled data analysis of available research found that ADHD drugs may successfully treat key aspects of Alzheimer's disease. Noradrenergic drugs, which target the neurotransmitter noradrenaline, showed a small but significant positive effect on overall cognition and a large positive effect on apathy in patients with Alzheimer's disease.

SourceBMJ Group·JournalJournal of Neurology Neurosurgery & Psychiatry·TypeSystematic review·DateJul 5, 2022

Tumor ‘signatures’ could provide key to more accurate treatment for deadliest cancers

Researchers have developed a framework to analyze chromosomal instability in human cancers, characterizing 17 different types of signatures. These signatures can predict how tumors respond to drugs and help identify future drug targets. The discovery aims to improve survival rates for millions of cancer patients worldwide.

SourceUniversity of Cambridge·JournalNature·TypeData/statistical analysis·DateJun 15, 2022

Molecule that combines three distinct technologies against most aggressive type of brain cancer is tested

Researchers have developed a molecule that uses nanotechnology, chemotherapy and a monoclonal antibody to target glioblastoma multiforme, the most aggressive type of brain cancer. The treatment showed promise in isolated cells and animal models, with significant reductions in tumor volume and no increased toxicity.

SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalInternational Journal of Pharmaceutics·DateJun 14, 2022

Researchers identify factors that contribute to alcoholic liver disease

A novel study has identified metabolic defects, impaired protein secretion, and altered phosphoproteomic signatures in alcohol-associated cirrhosis and hepatitis. These findings may lead to the development of new diagnostic and therapeutic approaches for a disease with limited treatment options.

SourceElsevier·JournalAmerican Journal Of Pathology·TypeExperimental study·DateJun 13, 2022

Transcranial stimulation lowers blood pressure in patients with resistant hypertension, study shows

A recent study published in Frontiers in Cardiovascular Medicine found that transcranial direct current stimulation (tDCS) can lower blood pressure in patients with resistant hypertension. After a single session or ten sessions, the treatment reduced peripheral and central blood pressure in some patients by up to 15 mmHg.

SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalFrontiers in Cardiovascular Medicine·DateJun 7, 2022

Promising compound kills range of hard-to-treat cancers by targeting a previously undiscovered vulnerability

A compound called ERX-41 has been shown to kill a range of hard-to-treat cancer types, including breast and ovarian cancers, by targeting a previously unexploited vulnerability. This could lead to new drugs being developed to fight these cancers, which currently have few effective treatments.

SourceUniversity of Texas Health Science Center at San Antonio·JournalNature Cancer·TypeExperimental study·DateJun 2, 2022

Not individual genes but the “mutational signatures” of many genes hold the key to better cancer therapies

Researchers have found that mutational signatures, which reflect a collection of mutations across the genome, can accurately predict drug response in cancer cells. The study suggests that these signatures may hold the key to better cancer therapies and could be used to predict treatment response.

SourceInstitute for Research in Biomedicine (IRB Barcelona)·JournalNature Communications·TypeComputational simulation/modeling·DateMay 26, 2022

‘Sting’ protein’s efforts to clean up brain cell damage may speed Parkinson’s disease progress

A Johns Hopkins Medicine study found that a protein called STING responds to clean-up signals in brain cells damaged by Parkinson’s disease by creating a cycle of inflammation that accelerates the disease’s progression. In mice with deactivated STING proteins, there was less microglial activity and brain cell death.

SourceJohns Hopkins Medicine·JournalProceedings of the National Academy of Sciences·DateMay 19, 2022

Study finds nanomedicine targeting lymph nodes key to triple negative breast cancer treatment

Researchers found that targeting both tumor and lymph node microenvironments with nanomedicine improves treatment response for metastatic triple negative breast cancer. Long-term tumor remission was achieved in mice models using nanoparticles to deliver immune-modulating drugs.

SourceMichigan Medicine - University of Michigan·JournalScience Translational Medicine·TypeExperimental study·DateMay 12, 2022

Study identifies potential target for treating childhood blood cancer

Researchers have pinpointed a possible new target for treating patients with juvenile myelomonocytic leukemia (JMML), a highly aggressive blood cancer. Treatment using anti-inflammatories showed promise in rescuing JMML-like symptoms in zebrafish, suggesting a potential new approach to combating the disease.

SourceeLife·JournaleLife·TypeExperimental study·DateMay 10, 2022